Neuropsychiatric Disease and Treatment (Sep 2023)
Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review
Abstract
Ning Ma,1– 3,* Lei Zhang,4,* Wufang Zhang,1– 3 Yingying He,1– 3 Chong Ye,4 Xin Li4 1Peking University Sixth Hospital, Beijing, People’s Republic of China; 2Peking University Institute of Mental Health, Beijing, People’s Republic of China; 3NHC Key Laboratory of Mental Health (Peking University), Beijing, People’s Republic of China; 4Xi’an Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ning Ma, Peking University Sixth Hospital, NO. 51 Huayuan North Road, Haidian District, Beijing, 100191, People’s Republic of China, Tel +86 010 82801939, Email [email protected]: Evidence of comparative benefits of long-acting injectable (LAI) antipsychotics in Asian patients with schizophrenia has been inconsistent. This scoping review aimed to synthesize the current evidence in the past ten years and provide an overview of efficacy, safety, treatment adherence, patient attitudes, and healthcare resource utilization of LAI in this population. A systematic search was conducted with a pre-defined search strategy in six electronic databases including Chinese National Knowledge Infrastructure (CNKI), Wanfang, PubMed, Embase, CINAHL, and PsycArticles. A total of 46 studies were included, including 15 cohort studies, 13 single-arm trials, 10 randomized controlled trials, four mirror-image studies, three cross-sectional studies, and one controlled clinical trial. Paliperidone palmitate once-monthly injection (27/46) and risperidone LAI (14/46) were the most frequently investigated LAIs. Compared with oral antipsychotic medications (OAMs), LAIs demonstrated a lower rate of relapse/hospitalization and comparable improvement in efficacy. Adverse events (AEs) were similar between LAIs and OAMs, although types and incidence varied. Significant reduction in the length of hospitalization and number of outpatient visits/inpatient admission was observed after initiation of LAIs. These findings suggest that LAI demonstrated comparable efficacy and safety among Asian populations with schizophrenia in comparison to OAMs. Better adherence and lower relapse were observed in patients receiving LAIs from published evidence. Future research is warranted to better understand the comprehensive performance of LAI in specific population or context.Plain Language Summary: LAI antipsychotic drugs for the maintenance treatment of schizophrenia have been considered the therapy of choice in case of poor adherence to treatment and frequent relapses. Few review studies focused on the benefits of LAI antipsychotics for schizophrenia in the Asian population have been conducted to date. Therefore, we conducted this scoping review to comprehensively summarize the current published evidence in terms of LAI efficacy, safety, treatment adherence, patient attitudes, and healthcare resource utilization in Asia.Keywords: long-acting injectable antipsychotics, schizophrenia, Asian, scoping review
